Cubist Systematic Strategies’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $10.6M | Buy |
13,889
+3,128
| +29% | +$2.33M | 0.05% | 530 |
|
|
2025
Q2 | $8.39M | Buy |
+10,761
| New | +$8.36M | 0.04% | 703 |
|
|
2025
Q1 | – | Sell |
-7,447
| Closed | -$6.2M | – | 3213 |
|
|
2024
Q4 | $5.75M | Sell |
7,447
-38,338
| -84% | -$31.7M | 0.04% | 751 |
|
|
2024
Q3 | $40.6M | Buy |
+45,785
| New | +$41.2M | 0.25% | 59 |
|
|
2024
Q1 | – | Sell |
-18,651
| Closed | -$13.3M | – | 4046 |
|
|
2023
Q4 | $10.9M | Buy |
18,651
+2,049
| +12% | +$1.2M | 0.07% | 406 |
|
|
2023
Q3 | $8.92M | Buy |
16,602
+2,590
| +18% | +$1.33M | 0.07% | 435 |
|
|
2023
Q2 | $6.57M | Buy |
14,012
+8,105
| +137% | +$3.4M | 0.04% | 680 |
|
|
2023
Q1 | $2.03M | Sell |
5,907
-40,805
| -87% | -$13.8M | 0.01% | 1668 |
|
|
2022
Q4 | $17.1M | Buy |
46,712
+15,610
| +50% | +$5.53M | 0.1% | 216 |
|
|
2022
Q3 | $10.1M | Sell |
31,102
-70,300
| -69% | -$22.3M | 0.06% | 479 |
|
|
2022
Q2 | $32.9M | Buy |
101,402
+15,062
| +17% | +$4.52M | 0.2% | 35 |
|
|
2022
Q1 | $24.7M | Buy |
86,340
+64,310
| +292% | +$16.6M | 0.21% | 34 |
|
|
2021
Q4 | $6.08M | Sell |
22,030
-98,186
| -82% | -$24.9M | 0.06% | 517 |
|
|
2021
Q3 | $27.8M | Buy |
120,216
+102,326
| +572% | +$25.3M | 0.35% | 6 |
|
|
2021
Q2 | $4.11M | Sell |
17,890
-53,988
| -75% | -$10.8M | 0.05% | 651 |
|
|
2021
Q1 | $13.4M | Buy |
71,878
+34,950
| +95% | +$6.84M | 0.17% | 95 |
|
|
2020
Q4 | $6.24M | Sell |
36,928
-49,924
| -57% | -$7.45M | 0.09% | 335 |
|
|
2020
Q3 | $12.9M | Buy |
86,852
+4,511
| +5% | +$698K | 0.19% | 78 |
|
|
2020
Q2 | $13.5M | Buy |
82,341
+4,512
| +6% | +$693K | 0.23% | 66 |
|
|
2020
Q1 | $10.8M | Buy |
77,829
+69,021
| +784% | +$9.48M | 0.29% | 55 |
|
|
2019
Q4 | $1.16M | Sell |
8,808
-58,328
| -87% | -$6.76M | 0.02% | 1068 |
|
|
2019
Q3 | $7.51M | Sell |
67,136
-39,473
| -37% | -$4.39M | 0.15% | 174 |
|
|
2019
Q2 | $11.8M | Buy |
106,609
+36,388
| +52% | +$4.29M | 0.22% | 86 |
|
|
2019
Q1 | $9.11M | Buy |
70,221
+69,477
| +9,338% | +$8.45M | 0.3% | 38 |
|
|
2018
Q4 | $86K | Sell |
744
-23,345
| -97% | -$2.61M | ﹤0.01% | 1786 |
|
|
2018
Q3 | $2.58M | Buy |
24,089
+2,872
| +14% | +$287K | 0.14% | 138 |
|
|
2018
Q2 | $1.81M | Buy |
21,217
+855
| +4% | +$70.2K | 0.09% | 273 |
|
|
2018
Q1 | $1.57M | Sell |
20,362
-27,411
| -57% | -$2.21M | 0.09% | 287 |
|
|
2017
Q4 | $4.04M | Buy |
+47,773
| New | +$4.06M | 0.21% | 69 |
|
|
2017
Q3 | – | Sell |
-6,408
| Closed | -$527K | – | 1919 |
|
|
2017
Q2 | $527K | Sell |
6,408
-23,738
| -79% | -$1.94M | 0.03% | 714 |
|
|
2017
Q1 | $2.54M | Sell |
30,146
-5,576
| -16% | -$447K | 0.18% | 108 |
|
|
2016
Q4 | $2.63M | Buy |
35,722
+29,193
| +447% | +$2.17M | 0.21% | 90 |
|
|
2016
Q3 | $524K | Buy |
6,529
+2,299
| +54% | +$184K | 0.03% | 691 |
|
|
2016
Q2 | $333K | Sell |
4,230
-25,030
| -86% | -$1.88M | 0.02% | 1019 |
|
|
2016
Q1 | $2.11M | Buy |
29,260
+1,386
| +5% | +$105K | 0.12% | 201 |
|
|
2015
Q4 | $2.35M | Buy |
27,874
+19,159
| +220% | +$1.59M | 0.14% | 172 |
|
|
2015
Q3 | $729K | Sell |
8,715
-20,024
| -70% | -$1.69M | 0.04% | 730 |
|
|
2015
Q2 | $2.4M | Sell |
28,739
-51,412
| -64% | -$3.92M | 0.12% | 218 |
|
|
2015
Q1 | $5.82M | Buy |
80,151
+22,430
| +39% | +$1.6M | 0.29% | 54 |
|
|
2014
Q4 | $3.98M | Sell |
57,721
-5,651
| -9% | -$381K | 0.22% | 74 |
|
|
2014
Q3 | $4.11M | Buy |
63,372
+38,035
| +150% | +$2.41M | 0.25% | 67 |
|
|
2014
Q2 | $1.57M | Buy |
+25,337
| New | +$1.51M | 0.09% | 304 |
|
Other funds holding LLY
Cubist Systematic Strategies's LLY Position: Q3 2025 in Review
Cubist Systematic Strategies increased its Eli Lilly (LLY) stake by 29% in Q3 2025, buying an estimated $2.33M and bringing the position to 13,889 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #530.
Cubist Systematic Strategies first reported a position in LLY in Q2 2014 and has held it in 42 quarters since. The position peaked at $40.6M in Q3 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Cubist Systematic Strategies held 13,889 shares of Eli Lilly worth $10.6M as of Q3 2025.
- Cubist Systematic Strategies bought 3,128 Eli Lilly shares in Q3 2025, an estimated $2.33M.
- Eli Lilly made up 0.05% of Cubist Systematic Strategies's portfolio in Q3 2025, its #530 holding.
- Cubist Systematic Strategies first reported a position in Eli Lilly in Q2 2014 and has held it in 42 quarters since.
- Cubist Systematic Strategies's Eli Lilly position peaked at $40.6M in Q3 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.